Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) attributable profit rose 25% to 764.8 million yuan in the first quarter from 609.7 million yuan in the year-ago period, according to a Tuesday filing with the Hong Kong bourse.
Earnings per share at the drug company increased 26% to 0.29 yuan from 0.23 yuanin the year-ago period.
Operating income declined 7.3% to 9.42 billion yuan from 10.2 billion yuan in the prior-year period.
Shares slipped 4% in Hong Kong during afternoon trading on Wednesday.